Vanguard Global Advisers
BIOA

Vanguard Global Advisers’s BioAge Labs BIOA Stock Holding History

Vanguard Global Advisers’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$781K Buy
31,865
+8,606
+37% +$155K ﹤0.01% 1884
2026
Q1 		$407K Buy
+23,259
New +$448K ﹤0.01% 2136

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Global Advisers's BIOA Position: Q2 2026 in Review

Vanguard Global Advisers increased its BioAge Labs (BIOA) stake by 37% in Q2 2026, buying an estimated $155K and bringing the position to 31,865 shares worth $781K. The position accounts for ﹤0.01% of the portfolio, ranked #1884.

Vanguard Global Advisers first reported a position in BIOA in Q1 2026 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Vanguard Global Advisers held 31,865 shares of BioAge Labs worth $781K as of Q2 2026.
  • Vanguard Global Advisers bought 8,606 BioAge Labs shares in Q2 2026, an estimated $155K.
  • BioAge Labs made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1884 holding.
  • Vanguard Global Advisers first reported a position in BioAge Labs in Q1 2026 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.